Skip to main content

Coccidioidomycosis

3
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
1 program
1
PosaconazolePhase 3Small Molecule
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
PosaconazolePhase 3Small Molecule1 trial
Active Trials
NCT00423267Completed16Est. May 2009
Nielsen BioSciences
Nielsen BioSciencesCA - San Diego
1 program
1
Spherule-derived coccidioidinPhase 31 trial
Active Trials
NCT00690092Completed113Est. Sep 2007
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Pathogenesis and Genetics of Disseminated or Refractory CoccidioidomycosisN/A1 trial
Active Trials
NCT02190266Recruiting400Est. Jul 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Sharp TherapeuticsPosaconazole
Nielsen BioSciencesSpherule-derived coccidioidin
Allergy TherapeuticsPathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis

Clinical Trials (3)

Total enrollment: 529 patients across 3 trials

POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)

Start: May 2007Est. completion: May 200916 patients
Phase 3Completed
NCT00690092Nielsen BioSciencesSpherule-derived coccidioidin

A Multi-center Study of Spherule-Derived Coccidioidin

Start: May 2005Est. completion: Sep 2007113 patients
Phase 3Completed
NCT02190266Allergy TherapeuticsPathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis

Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis

Start: Sep 2014Est. completion: Jul 2029400 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 529 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.